• Phare
  • Validé par KD/KO

Anticorps Polyclonal de lapin anti-PD-L1/CD274 (C-terminal)

PD-L1/CD274 (C-terminal) Polyclonal Antibody for IF, IHC, IP, WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IP, IHC, IF, ChIP, ELISA

Conjugaison

Non conjugué

N° de cat : 28076-1-AP

Synonymes

B7 H, B7 H1, B7 homolog 1, B7H1, CD274, CD274 molecule, PD L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, PD-L1, PD-L1/CD274 (C-terminal), Programmed death ligand 1



Applications testées

Résultats positifs en WBcellules A549 traitées par IFN gamma, cellules MDA-MB-231, cellules THP-1, tissu cardiaque de rat, tissu cardiaque de souris, tissu placentaire humain
Résultats positifs en IPtissu placentaire humain,
Résultats positifs en IHCtissu d'amygdalite humain, tissu de cancer du col de l'utérus humain, tissu de cancer du poumon humain, tissu de cancer du sein humain, tissu placentaire humain
il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
Résultats positifs en IFtissu d'amygdalite humain,

Dilution recommandée

ApplicationDilution
Western Blot (WB)WB : 1:300-1:1000
Immunoprécipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochimie (IHC)IHC : 1:500-1:2000
Immunofluorescence (IF)IF : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

28076-1-AP cible PD-L1/CD274 (C-terminal) dans les applications de WB, IP, IHC, IF, ChIP, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Réactivité citéerat, Humain, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène PD-L1/CD274 (C-terminal) Protéine recombinante Ag27557
Nom complet CD274 molecule
Masse moléculaire calculée 290 aa, 33 kDa
Poids moléculaire observé 45-50 kDa
Numéro d’acquisition GenBankBC074984
Symbole du gène CD274
Identification du gène (NCBI) 29126
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
Conditions de stockageStocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA.

Informations générales

PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis. 

What is the molecular weight of PD-L1? 

Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176-290 aa). 

What are the isoforms of PD-L1? 

According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions. 

What is the subcellular localization and tissue specificity of PD-L1? 

It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues. 

What is the function of PD-L1 in immune responses? 

PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681). 

How can PD-L1's implication in cancer be used as a drug target? 

In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375).


Protocole

Product Specific Protocols
WB protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-APDownload protocol
IHC protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-APDownload protocol
IF protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-APDownload protocol
IP protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
mouseIHC

ACS Cent Sci

Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment

Authors - Yang Liu
humanIF

Cell Rep Med

Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3

Authors - Qun Wang
human,mouseWB,IHC

Sci Adv

Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation

Authors - Wei Xiang
mouseWB

Sci Adv

Promoting the activation of T cells with glycopolymer-modified dendritic cells by enhancing cell interactions.

Authors - Liyin Yu
human,mouseWB,IHC

J Exp Clin Cancer Res

Anoikis resistance and immune escape mediated by Epstein-Barr virus-encoded latent membrane protein 1-induced stabilization of PGC-1α promotes invasion and metastasis of nasopharyngeal carcinoma

Authors - Chaoliang Liao
humanIHC

Biomaterials

Bacteria-mediated metformin-loaded peptide hydrogel reprograms the tumor immune microenvironment in glioblastoma

Authors - Lisheng Zhu